Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules INDICATION Zohydro® ER is an opioid agonist, extended-release, oral formulation of hydrocodone bitartrate indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. LIMITATIONS OF USE Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Zohydro ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Zohydro ER is not indicated for use as an as-needed analgesic. Please click here to see the Zohydro ER professional product labeling for the complete boxed warning and safety information. On April 24, 2015, Zohydro ER was acquired by a wholly-owned subsidiary of Pernix Therapeutics Holdings, Inc. For information about Zohydro ER, please click here.